@article {1925, title = {Differences in interleukin-6 and interleukin-17 expression in covid-19 post-mortem lung tissue biopsy compared with noncovid- 19}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {January 2023}, pages = {887-892}, type = {Original Article }, chapter = {887}, abstract = {

Background: COVID-19 has spread rapidly around the world. It is necessary to study lung tissue of postmortem COVID19 patients to determine the molecular alteration particularly the role of IL-6 and IL-17 in causing fatality. Objective: This study aims to determine the differences in the expressions of IL-6 and IL-17 in lung tissue of post-mortem COVID-19 patients compared to non-COVID-19 patients. This study also aimed to analyze the correlation between the expressions of IL-6 and IL-17 in lung tissue of post-mortem COVID-19 patients. Methods: This research is an observational analytic study with crosssectional approach. The samples were 15 paraffin blocks of post-mortem lung tissue biopsy of COVID-19 patients, and 15 paraffin blocks of inflammatory lung tissue biopsy or surgery of non-COVID-19 patients. IL-6 and IL-17 expressions were evaluated by immunohistochemical procedure. Result: There was a significant difference in the expression of IL-6 in the COVID-19 group and the non-COVID-19 group with a p-value = 0.001 (p \< 0.05). There was a significant difference in the expression of IL-17 in the COVID-19 group and the non-COVID-19 group with p-value = 0.001 (p \< 0.05). There was a significant correlation between the expressions of IL-6 and IL-17 in the COVID-19 group, with the Spearman coefficient value (rs) of 0.548 with p = 0.034 (p \< 0.05). Conclusion: There are differences in the expression of IL-6 and IL-17 between COVID-19 and non-COVID-19 lung tissue. There is a significant correlation between the expressions of IL-6 and IL-17 in post-mortem lung tissue of COVID-19 patients.

}, keywords = {Biopsy, COVID-19, IL-17, IL-6, Post mortem lung tissue.}, doi = {10.5530/pj.2022.14.184}, author = {Etty Hary Kusumastuti and Priangga Adi Wiratama and Grace Ariani and Stephanie Natasha Djuanda and Alphania Rahniayu and Nila Kurniasari and Dyah Fauziah and Anny Setijo Rahaju and Isnin Anang Marhana and Alfian Nur Rosyid and Dwi Wahyu and Gilang Muhammad Setyo Nugroho and Adhitri Anggoro and I Komang Rusgi Yandi and Bambang Pujo Semedi and Jilientasia Godrace Lilihata and Ummi Maimunah and Supriadi and Achmad Lefi and Lalu Galih Pratama Rinjani and Edi Suyanto and Ricardo Ardian Nugraha} } @article {1178, title = {Human Umbilical Cord Blood-derived Secretome Enhance Endothelial Progenitor Cells Migration on Hyperglycemic Conditions}, journal = {Pharmacognosy Journal}, volume = {12}, year = {2020}, month = {June 2020}, pages = {793-797}, type = {Original Article}, chapter = {793}, abstract = {

Hyperglycemia state is harmful to body{\textquoteright}s homeostasis. Uncontrolled hyperglycemic patients, especially patients with diabetes mellitus have a higher mortality risk of heart disease 2 to 4 times compared to non-hyperglycemic patients. Vascular endothelial impairment always been observed and found as a key feature of hyperglycemia state, which is correlated with reduced numbers and dysfunction of endothelial progenitor cells (EPCs). Objective: This paper aims to investigate the effect of hUCB-MSCs derived secretome treatment on the EPCs migration under hyperglycemia state. Materials and Methods: EPCs were isolated and cultured from peripheral blood samples and cultured for three days. Cultured EPCs were cultivated in 6-well plates until confluence and incubated with high glucose for 5 days, then placed in the modified Boyden chamber at the upper chamber with basal media. The lower chamber was supplemented with basal media and secretome at 2\%, 10\%, and 20\% concentration and VEGF treated group as a control. EPCS migration was evaluated using a Boyden chamber assay. Statistical analysis was performed using SPS 25.0. Results: EPCs migration were significantly higher when hUCB-MSCs-derived secretome was given in high glucose concentrations compared to the and control group (79.80 {\textpm} 5.07 vs 51.00 {\textpm} 5.15, p\<0.000). This study also showed that hUCB-MSCs-derived secretome increase EPCs migration under high glucose concentrations in a dose-dependent manner (p\<0.05). Conclusion: hUCB-MSCsderived secretome enhances EPCs migration under hyperglycemic state. This result may be of relevance for cell-free and regenerative therapeutic modality for a diabetic patient with coronary artery disease (CAD).

}, keywords = {Endothelial progenitor cells, Hyperglycemia state, Mesenchymal stem cells, Migration, Secretome}, doi = {10.5530/pj.2020.12.113}, author = {Yudi Her Oktaviono and Melly Susanti and Achmad Lefi and Ferry Sandra} }